Off-the shelf immune cell therapies are potentially curative and may offer cost and manufacturing advantages over autologous products, but further development is needed. The NK92 cell line has a natural killer-like phenotype, has efficacy in cancer clinical trials, and is safe after irradiation. However, NK92 cells lose activity post-injection, limiting efficacy. This may be addressed by engineering NK92 cells to express stimulatory factors, and comparative analysis is needed. Thus, we systematically explored the expression of synthetic cytokines for enhancing NK92 cell production and performance. All synthetic cytokines evaluated (membrane-bound IL2 and IL15, and engineered versions of Neoleukin-2/15, IL15, IL12, and decoy resistant IL18) enhanced NK92 cell cytotoxicity. Engineered cells were preferentially expanded by expressing membrane-bound but not soluble synthetic cytokines, without compromising the radiosensitivity required for safety. Some membrane-bound cytokines conferred cell-contact independent paracrine activity, partly attributable to extracellular vesicles. Finally, we characterized interactions within consortia of differently engineered NK92 cells.
Get full access to this article
View all access options for this article.
References
1.
PatelS, BurgaRA, PowellAB, et al.Beyond CAR T cells: Other cell-based immunotherapeutic strategies against cancer. Front Oncol, 2019; 9:196; doi: 10.3389/fonc.2019.00196
2.
CappellKM, KochenderferJN. Long-term outcomes following CAR T cell therapy: What we know so far. Nat Rev Clin Oncol, 2023; 1–13; doi: 10.1038/s41571-023-00754-1
3.
SternerRC, SternerRM. CAR-T cell therapy: Current limitations and potential strategies. Blood Cancer J, 2021; 11(4):69; doi: 10.1038/s41408-021-00459-7
4.
IchikiY, BowlusCL, ShimodaS, et al.T cell immunity and graft-versus-host disease (GVHD). Autoimmun Rev, 2006; 5(1):1–9; doi: 10.1016/j.autrev.2005.02.006
5.
BegunC.Penn Researchers Shorten Manufacturing for CAR T Cell Therapy. Penn Medicine News; 2022.
6.
NamS, SmithJ., YangG.Driving the Next Wave of Innovation in CAR T-Cell Therapies. McKinsey & Company; 2019.
7.
LiuS, GalatV, GalatY, et al.NK cell-based cancer immunotherapy: From basic biology to clinical development. J Hematol Oncol, 2021; 14(1):7; doi: 10.1186/s13045-020-01014-w
8.
LiuE, MarinD, BanerjeeP, et al.Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med, 2020; 382(6):545–553; doi: 10.1056/NEJMoa1910607
9.
MalmbergKJ, CarlstenM, BjorklundA, et al.Natural killer cell-mediated immunosurveillance of human cancer. Semin Immunol, 2017; 31:20–29; doi: 10.1016/j.smim.2017.08.002
10.
KlingemannH, BoisselL, ToneguzzoF. Natural killer cells for immunotherapy—Advantages of the NK-92 cell line over blood NK cells. Front Immunol, 2016; 7:91; doi: 10.3389/fimmu.2016.00091
11.
GongJH, MakiG, KlingemannHG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia, 1994; 8(4):652–658
12.
FabianKP, HodgeJW. The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy. Mol Ther Oncolytics, 2021; 23:266–276; doi: 10.1016/j.omto.2021.10.001
13.
SpinkK, SteinsapirA. The long road to affordability: A cost of goods analysis for an autologous CAR-T process. Cell Gene Ther Insights, 2018; 4:1105–1116; doi: 10.18609/cgti.2018.108
14.
ChaudhariN, RickardAM, RoyS, et al.A non-viral genome editing platform for site-specific insertion of large transgenes. Stem Cell Res Ther, 2020; 11(1):380; doi: 10.1186/s13287-020-01890-6
15.
BerraondoP, SanmamedMF, OchoaMC, et al.Cytokines in clinical cancer immunotherapy. Br J Cancer, 2019; 120(1):6–15; doi: 10.1038/s41416-018-0328-y
16.
ZhengX, WuY, BiJ, et al.The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy. Cell Mol Immunol, 2022; 19(2):192–209; doi: 10.1038/s41423-021-00786-6
PachellaLA, MadsenLT, DainsJE. The toxicity and benefit of various dosing strategies for interleukin-2 in metastatic melanoma and renal cell carcinoma. J Adv Pract Oncol, 2015; 6(3):212–221
19.
LacyMQ, JacobusS, BloodEA, et al.Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): A trial of the Eastern Cooperative Oncology Group. Leuk Res, 2009; 33(11):1485–1489; doi: 10.1016/j.leukres.2009.01.020
20.
LuoH, WuX, SunR, et al.Target-dependent expression of IL12 by synNotch receptor-engineered NK92 cells increases the antitumor activities of CAR-T cells. Front Oncol, 2019; 9:1448; doi: 10.3389/fonc.2019.01448
21.
JounaidiY, CottenJF, MillerKW, et al.Tethering IL2 to its receptor IL2Rbeta enhances antitumor activity and expansion of natural killer NK92 cells. Cancer Res, 2017; 77(21):5938–5951; doi: 10.1158/0008-5472.CAN-17-1007
22.
GuoM, SunC, QianY, et al.Proliferation of highly cytotoxic human natural killer cells by OX40L armed NK-92 with secretory neoleukin-2/15 for cancer immunotherapy. Front Oncol, 2021; 11:632540; doi: 10.3389/fonc.2021.632540
23.
SieglerEL, WangP. Abstract A59: Expression of membrane-bound IL-15/IL-15Rα complex in chimeric antigen receptor-engineered natural killer cells for enhanced efficacy against solid tumors [abstract]. Cancer Immunol Res, 2018; 6(9_, Supplement):A59.
24.
LieschkeGJ, RaoPK, GatelyMK, et al.Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo. Nat Biotechnol, 1997; 15(1):35–40; doi: 10.1038/nbt0197-35
25.
SilvaDA, YuS, UlgeUY, et al.De novo design of potent and selective mimics of IL-2 and IL-15. Nature, 2019; 565(7738):186–191; doi: 10.1038/s41586-018-0830-7
26.
ZhouT, DamskyW, WeizmanOE, et al.IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy. Nature, 2020; 583(7817):609–614; doi: 10.1038/s41586-020-2422-6
27.
MortierE, QuemenerA, VusioP, et al.Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins. J Biol Chem, 2006; 281(3):1612–1619; doi: 10.1074/jbc.M508624200
28.
HurtonLV, SinghH, NajjarAM, et al.Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc Natl Acad Sci U S A, 2016; 113(48):E7788–E7797; doi: 10.1073/pnas.1610544113
ChambersAM, MatosevicS. Immunometabolic dysfunction of natural killer cells mediated by the hypoxia-CD73 axis in solid tumors. Front Mol Biosci, 2019; 6:60; doi: 10.3389/fmolb.2019.00060
31.
VincentM, BessardA, CochonneauD, et al.Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency. Int J Cancer, 2013; 133(3):757–765; doi: 10.1002/ijc.28059
32.
ZwirnerNW, ZiblatA. Regulation of NK cell activation and effector functions by the IL-12 family of cytokines: The case of IL-27. Front Immunol, 2017; 8:25; doi: 10.3389/fimmu.2017.00025
33.
TrinchieriG.Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol, 1995; 13:251–276; doi: 10.1146/annurev.iy.13.040195.001343
34.
TornroosH, HagerstrandH, LindqvistC. Culturing the human natural killer cell line NK-92 in interleukin-2 and interleukin-15—Implications for clinical trials. Anticancer Res, 2019; 39(1):107–112; doi: 10.21873/anticanres.13085
35.
KalinaU, KauschatD, KoyamaN, et al.IL-18 activates STAT3 in the natural killer cell line 92, augments cytotoxic activity, and mediates IFN-gamma production by the stress kinase p38 and by the extracellular regulated kinases p44erk-1 and p42erk-21. J Immunol, 2000; 165(3):1307–1313; doi: 10.4049/jimmunol.165.3.1307
36.
ImamuraM, ShookD, KamiyaT, et al.Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15. Blood, 2014; 124(7):1081–1088; doi: 10.1182/blood-2014-02-556837
37.
SweeneyNP, VinkCA. The impact of lentiviral vector genome size and producer cell genomic to gag-pol mRNA ratios on packaging efficiency and titre. Mol Ther Methods Clin Dev, 2021; 21:574–584; doi: 10.1016/j.omtm.2021.04.007
38.
ZhangB, ZhangJ, TianZ. Comparison in the effects of IL-2, IL-12, IL-15 and IFNalpha on gene regulation of granzymes of human NK cell line NK-92. Int Immunopharmacol, 2008; 8(7):989–996; doi: 10.1016/j.intimp.2008.03.001
39.
RossME, CaligiuriMA. Cytokine-induced apoptosis of human natural killer cells identifies a novel mechanism to regulate the innate immune response. Blood, 1997; 89(3):910–918
40.
IannelloA, SamaraniS, DebbecheO, et al.Potential role of interleukin-18 in the immunopathogenesis of AIDS: Involvement in fratricidal killing of NK cells. J Virol, 2009; 83(12):5999–6010; doi: 10.1128/JVI.02350-08
FerreiraJP, OvertonKW, WangCL. Tuning gene expression with synthetic upstream open reading frames. Proc Natl Acad Sci U S A, 2013; 110(28):11284–11289; doi: 10.1073/pnas.1305590110
43.
SarojiniS, PecoraA, MilinovikjN, et al.A combination of high dose rate (10X FFF/2400 MU/min/10 MV X-rays) and total low dose (0.5 Gy) induces a higher rate of apoptosis in melanoma cells in vitro and superior preservation of normal melanocytes. Melanoma Res, 2015; 25(5):376–389; doi: 10.1097/CMR.0000000000000174
44.
GaggeroS, Martinez-FabregasJ, CozzaniA, et al.IL-2 is inactivated by the acidic pH environment of tumors enabling engineering of a pH-selective mutein. Sci Immunol, 2022; 7(78):eade5686; doi: 10.1126/sciimmunol.ade5686
45.
BessardA, SoleV, BouchaudG, et al.High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer. Mol Cancer Ther, 2009; 8(9):2736–2745; doi: 10.1158/1535-7163.MCT-09-0275
46.
PengLS, PenichetML, MorrisonSL. A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity. J Immunol, 1999; 163(1):250–258
47.
Navarrete-GalvanL, GuglielmoM, Cruz AmayaJ, et al.Optimizing NK-92 serial killers: Gamma irradiation, CD95/Fas-ligation, and NK or LAK attack limit cytotoxic efficacy. J Transl Med, 2022; 20(1):151; doi: 10.1186/s12967-022-03350-6
48.
BalsamoM, ManziniC, PietraG, et al.Hypoxia downregulates the expression of activating receptors involved in NK-cell-mediated target cell killing without affecting ADCC. Eur J Immunol, 2013; 43(10):2756–2764; doi: 10.1002/eji.201343448
49.
AlizadehD, WongRA, GholaminS, et al.IFNgamma is critical for CAR T cell-mediated myeloid activation and induction of endogenous immunity. Cancer Discov, 2021; 11(9):2248–2265; doi: 10.1158/2159-8290.CD-20-1661
50.
WuestSC, EdwanJH, MartinJF, et al.A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat Med, 2011; 17(5):604–609; doi: 10.1038/nm.2365
51.
StonierSW, SchlunsKS. Trans-presentation: A novel mechanism regulating IL-15 delivery and responses. Immunol Lett, 2010; 127(2):85–92; doi: 10.1016/j.imlet.2009.09.009
52.
BuzasEI.The roles of extracellular vesicles in the immune system. Nat Rev Immunol, 2022; 1–15; doi: 10.1038/s41577-022-00763-8
53.
MaricchioloE, PanfiliE, PompaA, et al.Unconventional pathways of protein secretion: Mammals vs. plants. Front Cell Dev Biol, 2022; 10:895853; doi: 10.3389/fcell.2022.895853
54.
van NielG, D'AngeloG, RaposoG. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol, 2018; 19(4):213–228; doi: 10.1038/nrm.2017.125
55.
LischnigA, BergqvistM, OchiyaT, et al.Quantitative proteomics identifies proteins enriched in large and small extracellular vesicles. Mol Cell Proteomics, 2022; 21(9):100273; doi: 10.1016/j.mcpro.2022.100273
56.
ThéryC, WitwerKW, AikawaE, et al.Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles, 2018; 7(1):1535750; doi: 10.1080/20013078.2018.1535750
57.
NordinJZ, LeeY, VaderP, et al.Ultrafiltration with size-exclusion liquid chromatography for high yield isolation of extracellular vesicles preserving intact biophysical and functional properties. Nanomedicine, 2015; 11(4):879–883; doi: 10.1016/j.nano.2015.01.003
58.
SharabiA, LiH, KasperIR, et al.PP2A enables IL-2 signaling by preserving IL-2Rbeta chain expression during Treg development. JCI Insight, 2019; 5(9); doi: 10.1172/jci.insight.126294
59.
TamzalitF, BarbieuxI, PletA, et al.IL-15.IL-15Ralpha complex shedding following trans-presentation is essential for the survival of IL-15 responding NK and T cells. Proc Natl Acad Sci U S A, 2014; 111(23):8565–8570; doi: 10.1073/pnas.1405514111
60.
PilletAH, JuffroyO, Mazard-PasquierV, et al.Human IL-Rbeta chains form IL-2 binding homodimers. Eur Cytokine Netw, 2008; 19(1):49–59; doi: 10.1684/ecn.2008.0120
61.
MyersJA, SchirmD, BendzickL, et al.Balanced engagement of activating and inhibitory receptors mitigates human NK cell exhaustion. JCI Insight, 2022; 7(15):e150079; doi: 10.1172/jci.insight.150079
62.
FrenchAR, HolroydEB, YangL, et al.IL-18 acts synergistically with IL-15 in stimulating natural killer cell proliferation. Cytokine, 2006; 35(5–6):229–234; doi: 10.1016/j.cyto.2006.08.006
63.
TapiaVS, DanielsMJD, Palazon-RiquelmeP, et al.The three cytokines IL-1beta, IL-18, and IL-1alpha share related but distinct secretory routes. J Biol Chem, 2019; 294(21):8325–8335; doi: 10.1074/jbc.RA119.008009
64.
WaldmannT.The contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: Implications for the immunotherapy of rheumatological diseases. Arthritis Res, 2002; 4Suppl 3(Suppl 3):S161–S167; doi: 10.1186/ar584
65.
FelicesM, LenvikAJ, McElmurryR, et al.Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect. JCI Insight, 2018; 3(3); doi: 10.1172/jci.insight.96219
66.
OuyangS, HsuchouH, KastinAJ, et al.TNF stimulates nuclear export and secretion of IL-15 by acting on CRM1 and ARF6. PLoS One, 2013; 8(8):e69356; doi: 10.1371/journal.pone.0069356
ChenX, ZaroJL, ShenWC. Fusion protein linkers: Property, design and functionality. Adv Drug Deliv Rev, 2013; 65(10):1357–1369; doi: 10.1016/j.addr.2012.09.039
69.
StrackRL, StronginDE, BhattacharyyaD, et al.A noncytotoxic DsRed variant for whole-cell labeling. Nat Methods, 2008; 5(11):955–957; doi: 10.1038/nmeth.1264
70.
BindelsDS, HaarboschL, van WeerenL, et al.mScarlet: A bright monomeric red fluorescent protein for cellular imaging. Nat Methods, 2017; 14(1):53–56; doi: 10.1038/nmeth.4074
71.
DeolS, DonahuePS, MitrutRE, et al.Source Data for “Comparative evaluation of synthetic cytokines for enhancing production and performance of NK92 cell-based therapies”. Zenodo, 2023: doi: 10.5281/zenodo.8047841
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
